Monday 18th September 2023 |
Text too small? |
TruScreen Group Limited (NZX/ASX:TRU) is pleased to report that the Dr Sulaiman Al-Habib Medical Group, has installed the first tranche of four TruScreen devices for commercial use, for the screening of cervical cancer in Saudi Arabia.
Dr Sulaiman Al-Habib Medical Group (DSAMG) is the largest private hospital network in the Middle East. The adoption of TruScreen’s screening technology by DSAMG private hospitals will be important reference sites for further market access in neighbouring Middle Eastern nations.
This installation follows from the previously announced successful completion of the clinical evaluation by DSAMG network, followed by a successful tender by BettaLife Trading FZC (BettaLife) (Truescreen’s distributor in the Middle East).
The excellent clinical results of the evaluation were announced previously: see link
https://www.nzx.com/announcements/408275
TruScreen’s CEO, Dr Beata Edling said:
“I am very pleased that the Dr Sulaiman Al-Habib Medical Group have approved and will use TruScreen technology to advance the screening for cervical cancer in their hospital network.
We congratulate BettaLife, our partner in Saudi Arabia, on reaching this important milestone which will support the expansion of the TruScreen operations in the Middle East.”
This announcement has been approved by the Board.
Ends
Commercial Breakthrough in Saudi Arabia - Commences use of TruScreen Technology
No comments yet
ARB - Annual Meeting Date and Director Nominations
CNU - Q4 FY25 Connections Update
MOVE FY25 Results and Investor Briefing 29 August 2025
RYM - First quarter trading update
July 11th Morning Report
IKE Announces equity raising of A$20 million
Chorus full year results date
FPH 2025 Notice of Annual Meeting and Voting Form
July 10th Morning Report
July 9th Morning Report